ALK and non-small cell lung carcinoma: The ALK (anaplastic lymphoma Kinase) inhibitor crizotinib, has recently shown high efficacy in the treatment of patients with non-small cell lung cancer (NSCLC) with ALK translocation which is present in about 4–7% of the tumors [10]–[12].